Long-term Follow-up Study of BRL-101 for TDT

Recruiting now

Conditions studied: Thalassemia, Beta

In brief

Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

Key facts

Study ID

NCT06298630

Run by

Bioray Laboratories

People needed

45

Starts

2024-12-08

Expected to finish

2038-10-15

Last updated by the study team

2026-07-21

Who can join

Age: 3 and older, up to 35. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
• Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.

You may not qualify if…

• There are no exclusion criteria for this study

Where it is running

• Xiangya Hospital of Central South University — Changsha, Hunan, China (enrolling)
• Tianjin Institute of Hematology — Tianjin, Tianjin Municipality, China (enrolling)
• The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY — Guangxi, China (enrolling)
• Nanfang Hospital, Southern Medical University — Guangzhou, Guangdong, China
• No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital — Nanning, Guangxi, China
• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University — Guangzhou, Guangdong, China
• Shenzhen Children 's Hospital — Shenzhen, Guangdong, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.